ZF Friedrichshafen, einer der größten Automobilzulieferer weltweit, steht unter erheblichem wirtschaftlichen Druck. Als Reaktion auf die angespannte Lage wird am Stammsitz des Konzerns in Friedrichsha ...

Building on its strong global momentum, On achieves record quarterly net sales of CHF 726.6 million in the first quarter, growing by 43.0% year-over-year, 40.0% on a constant currency basis. The ...

Freemelt has entered a strategic partnership with Scanfil. Under the agreement, Freemelt will outsource the full manufacturing of its advanced 3D printers. This transition represents an important mile ...

The Board of Directors of Nimbus Group has appointed Johan Inden as the new CEO of Nimbus Group AB, with the appointment taking effect 1:st of September. Johan Inden succeeds Jan-Erik Lindström, who e ...

An der Börse notiert die Aktie von Ramelius Resources zur Stunde leichter. Das Papier notiert gegenwärtig bei 1,48 Euro. Das Wertpapier von Ramelius Resources verzeichnet derzeit einen Abschlag von 1, ...

Team, Inc. (NYSE: TISI) ("TEAM" or the "Company"), a global, leading provider of specialty industrial services offering customers access to a full ...

Exodus Movement, Inc. (NYSE American: EXOD) ("Exodus"), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the first ...

Total revenue increased 17% to $134.1 million Net income of $8.0 million at a 6% margin; adjusted EBITDA of $41.5 million at a 31% margin Raises midpoint of full-year ...

Matthews Memorialization, a division of Matthews International Corporation (NASDAQ GSM: MATW) ("Matthews"), today announced it has acquired The Dodge Company ...

HighPeak Energy, Inc. ("HighPeak" or the "Company") (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025 ...

HIGHLIGHTS Q1 consolidated Net Revenue of $1,092 million and strong Adjusted EBITDA both outperformed expectations. Q1 Total Segment Operating Income increased 9.7%.

Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r ...